注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Relmada Therapeutics Inc是一家臨床階段的生物技術公司。該公司專注於開發艾美沙酮(d-美沙酮,dextromethadone,REL-1017),一種N-甲基-D-天冬氨酸(NMDA)受體拮抗劑。該公司的主要候選產品艾美沙酮是一種新型化學實體(NCE),開發為一種用於治療抑鬱症、中樞神經系統(CNS)疾病和其他潛在適應症的快速作用的口服藥物。該公司的主導項目REL-1017是一種新型NMDA受體(NMDAR)通道阻滯劑,優先靶向過度活躍的通道,同時維持生理性谷氨酸能神經傳遞,並且正在開髮用於重度抑鬱症(MDD)的輔助或單一療法。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Maged S. Shenouda | 60 | 2020 | Chief Financial Officer |
Paul E. Kelly | 67 | 2015 | Director |
Dan Iosifescu | - | 2020 | Member of Scientific Advisory Board |
John Glasspool | 61 | 2019 | Independent Director |
Charles E. Inturrisi | - | - | Member of Scientific Advisory Board |
Stephen M. Stahl | - | 2020 | Member of Scientific Advisory Board |
Sergio Traversa | 64 | 2012 | CEO & Director |
Maurizio Fava | - | 2017 | Member of Scientific Advisory Board |
Charles J. Casamento | 79 | 2015 | Independent Chairman of the Board |
Thomas P. Laughren | - | 2020 | Member of Scientific Advisory Board |
Luca Pani | - | 2020 | Member of Scientific Advisory Board |
Sanjay Johan Mathew | - | 2020 | Member of Scientific Advisory Board |
Fabiana Fedeli | 53 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核